Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
18 janv. 2022 08h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences to Present at Upcoming Investor Conferences
17 nov. 2021 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h05 HE
|
Caribou Biosciences, Inc.
On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010 Expanded leadership with appointments of Ran Zheng and Dara...
Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer
08 nov. 2021 09h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou Biosciences to Present at Upcoming Investor Conferences
20 oct. 2021 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors
29 sept. 2021 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has...
Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
27 sept. 2021 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results
02 sept. 2021 16h05 HE
|
Caribou Biosciences, Inc.
Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters’ option to purchase additional shares ANTLER Phase 1...
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology
02 sept. 2021 16h05 HE
|
Caribou Biosciences, Inc.
Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications ...